Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

被引:2234
|
作者
Cua, DJ
Sherlock, J
Chen, Y
Murphy, CA
Joyce, B
Seymour, B
Lucian, L
To, W
Kwan, S
Churakova, T
Zurawski, S
Wiekowski, M
Lira, SA
Gorman, D
Kastelein, RA
Sedgwick, JD
机构
[1] DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA
[2] DNAX Res Inst Mol & Cellular Biol Inc, Dept Genom, Palo Alto, CA 94304 USA
[3] DNAX Res Inst Mol & Cellular Biol Inc, Dept Prot & Antibody Technol, Palo Alto, CA 94304 USA
[4] Schering Plough Corp, Res Inst, Dept Immunol, Kenilworth, NJ 07033 USA
关键词
D O I
10.1038/nature01355
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Interleukin-12 (IL-12) is a heterodimeric molecule composed of p35 and p40 subunits. Analyses in vitro have defined IL-12 as an important factor for the differentiation of naive T cells into T-helper type 1 CD4(+) lymphocytes secreting interferon-gamma (refs 1, 2). Similarly, numerous studies(3-7) have concluded that IL-12 is essential for T-cell-dependent immune and inflammatory responses in vivo, primarily through the use of IL-12 p40 gene-targeted mice and neutralizing antibodies against p40. The cytokine IL-23, which comprises the p40 subunit of IL-12 but a different p19 subunit(8), is produced predominantly by macrophages and dendritic cells, and shows activity on memory T cells. Evidence from studies of IL-23 receptor expression(9) and IL-23 overexpression in transgenic mice(10) suggest, however, that IL-23 may also affect macrophage function directly. Here we show, by using gene-targeted mice lacking only IL-23 and cytokine replacement studies, that the perceived central role for IL-12 in autoimmune inflammation, specifically in the brain, has been misinterpreted and that IL-23, and not IL-12, is the critical factor in this response. In addition, we show that IL-23, unlike IL-12, acts more broadly as an end-stage effector cytokine through direct actions on macrophages.
引用
收藏
页码:744 / 748
页数:5
相关论文
共 50 条
  • [41] Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases
    Adorini, L
    CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (12) : 1610 - 1625
  • [42] Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases
    L. Adorini
    Cellular and Molecular Life Sciences CMLS, 1999, 55 : 1610 - 1625
  • [43] Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Jaber, Fouad
    Ayyad, Mohammed
    Alsakarneh, Saqr
    Alsharaeh, Tala
    Salahat, Ahmed-Jordan
    Jaber, Mohammad
    Gangwani, Manesh Kumar
    Abboud, Yazan
    Mohamed, Islam
    Ali, Hassam
    Kilani, Yassine
    Farraye, Francis A.
    Hashash, Jana G.
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e17 - e29
  • [44] Interleukin-12/23 vs Interleukin-23 Inhibitors in Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis
    Pasam, Ravi Teja
    Gautam, Misha
    Venugopalan, Sruthi
    Mohan, Babu
    Navaneethan, Udaykumar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S834 - S835
  • [45] Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1
    Kamata, M.
    Tada, Y.
    Tatsuta, A.
    Kawashima, T.
    Shibata, S.
    Mitsui, H.
    Asano, Y.
    Sugaya, M.
    Kadono, T.
    Kanda, N.
    Watanabe, S.
    Sato, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2013, 38 (05) : 545 - 548
  • [46] Interleukin-12 to interleukin ‘infinity’: the rationale for future therapeutic cytokine targeting
    E. J. R. Anderson
    M. A. McGrath
    T. Thalhamer
    I. B. McInnes
    Springer Seminars in Immunopathology, 2006, 27 : 425 - 442
  • [47] Interleukin-12 to interleukin 'infinity': the rationale for future therapeutic cytokine targeting
    Anderson, E. J. R.
    McGrath, M. A.
    Thalhamer, T.
    McInnes, I. B.
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2006, 27 (04): : 425 - 442
  • [48] Interleukin-12/23 and Interleukin-23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi-Institutional Registry
    Mckay, G. E.
    Coromilas, A.
    Liu, L.
    Shaw, K. S.
    Murphy, M.
    Punyamurthy, N.
    Soltero, K. M. Santiago
    Damsky, W.
    Wanat, K. A.
    Charrow, A. P.
    Rosenbach, M.
    Caplan, A.
    Lasenna, C. E.
    Arkin, L.
    Shields, B. E.
    JEADV CLINICAL PRACTICE, 2025,
  • [49] Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis
    Zhong, Zhenyu
    Su, Guannan
    Kijlstra, Aize
    Yang, Peizeng
    PROGRESS IN RETINAL AND EYE RESEARCH, 2021, 80
  • [50] Interleukin-12: A proinflammatory cytokine with immunoregulatory functions
    Trinchieri, G
    Scott, P
    RESEARCH IN IMMUNOLOGY, 1995, 146 (7-8): : 423 - 431